Trial
NCT02193074
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Biogen
Collaborators
—
Condition
Spinal Muscular Atrophy
Intervention
nusinersen
Why stopped
After a positive interim analysis, the decision was made to terminate the study early to allow for participants to enroll into an open label study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-17